|
EDUCATION - B.S. 2002, University of Wisconsin-Madison
Pharmacology/Toxicology
RESEARCH EXPERIENCE - University of Wisconsin-McArdle Laboratory for Cancer Research; June 2002-present.
Advisor - Christopher A. Bradfield, PhD
Project - The Bradfield Lab focuses on how the Aryl Hydrocarbon Receptor (AhR) mediates toxic responses and AhR's role during development. I am currently mapping genetic modifiers of dioxin-induced cleft palate. - University of Wisconsin Comprehensive Cancer Center, 1998 - 2002
Advisor - John E. Niederhuber, MD, UWCCC Director
Project - The Niederhuber lab studies the src-like kinase, Blk. I studied a putative Internal Ribosomal Entry Site within the 5' untranslated region of blk mRNA.
PUBLICATIONS - Dunham EE, Stevens EA, Glover E, Bradfield CA. The aryl hydrocarbon receptor signaling pathway is modified through interactions with a kelch protein. Mol Pharmacol. 70:8-15, 2006.
- Thomae TL, Stevens EA, Liss AL, Drinkwater NR, Bradfield CA. The terarogenic sensitivity to 2,3,7,8-tetrachlorodibenzo-p-dioxin is modified by a locus on mouse chrosome 3. Molecular Pharmacology 69:770-775, 2006.
- Thomae TL, Stevens EA, Bradfield CA. Transforming growth factor-beta3 restores fusion in palatal shelves exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem 280:12742-12746, 2005.
PRESENTATIONS - Short Course on Complex Trait Analysis, Jackson Labs, Bar Harbor ME, 2007.
- Days of Molecular Medicine Symposium, "Emerging Technologies and Cancer Biology," Boston MA, 2007.
- Short Course on Complex Trait Analysis, Jackson Labs, Bar Harbor ME, 2007.
- The 47th Annual Short Course on Medical and Experimental Mammalian Genetics, Jackson Labs, Bar Harbor ME, 2006.
- The American Association for Cancer Research Annual Meeting in San Francisco in March 2002
- The Genetic/Genomic Analysis of Human Biology Conference at UW-Madison in June, 2001.
ABSTRACTS - Kahl B, McGovern J, Blank J, Jaslowski A, Bayer G, Bottner W, Rezazadeh H, McFarland T, Hei D, Smith J, Stevens E, Eickhoff J, Longo W. Phase II Study of Modified Hyper-CVAD with Rituximab Maintenance for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. The Journal of the American Society of Hematology, 2004
- Kahl B, Ahuja H, Sanchez F, Rodrigues G, Voorhees P, Stevens E, Smith J, Turman N, Kim K, Bailey H. Phase II Study of Arsenic Trioxide Plus Ascorbic Acid for Relapsed and Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study. The Journal of the American Society of Hematology, 2004.
|
